Skip to main content

Gilead Sciences Yeztugo revenue

  • GILD · Nasdaq
  • Biotechnology
  • S&P 500
$168.08+0.08%Close 13 Nov 2026 · Market value $210.1B

Yeztugo revenue at Gilead Sciences came to $305.0M for the quarter to 30 Sep 2026, up 682.1% from a year earlier.

As Gilead Sciences reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 30 Oct 2026.

By quarter

$0Mar 2025$15.0MJun 2025$39.0MSep 2025$166.0MMar 2026$232.0MJun 2026$305.0MSep 2026
Gilead Sciences Yeztugo revenue, every reported period
Period endingYeztugo revenueChange on a yearFiled
30 Sep 2026$305.0Mup 682.1%30 Oct 2026
30 Jun 2026$232.0Mup 1446.7%6 Aug 2026
31 Mar 2026$166.0M—7 May 2026
30 Sep 2025$39.0M—7 Nov 2025
30 Jun 2025$15.0M—7 Aug 2025
31 Mar 2025$0—7 May 2025

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of Gilead Sciences: Product sales · Biktarvy revenue · Descovy revenue · Trodelvy revenue · Genvoya revenue · Vemlidy revenue · Yescarta revenue · Odefsey revenue · Sofosbuvir/Velpatasvir revenue · Livdelzi revenue · Symtuza - Revenue share revenue · AmBisome revenue · Veklury revenue · Tecartus revenue · Royalty, contract and other revenues · United States revenue · Europe revenue · Rest of World revenue · financial statements

Every KPI and segment of GILD, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.